Mutations in FUS lead to synaptic dysregulation in ALS-iPSC derived neurons

Stem Cell Reports. 2024 Feb 13;19(2):187-195. doi: 10.1016/j.stemcr.2023.12.007. Epub 2024 Jan 18.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disorder characterized by progressive muscular weakness due to the selective loss of motor neurons. Mutations in the gene Fused in Sarcoma (FUS) were identified as one cause of ALS. Here, we report that mutations in FUS lead to upregulation of synaptic proteins, increasing synaptic activity and abnormal release of vesicles at the synaptic cleft. Consequently, FUS-ALS neurons showed greater vulnerability to glutamate excitotoxicity, which raised neuronal swellings (varicose neurites) and led to neuronal death. Fragile X mental retardation protein (FMRP) is an RNA-binding protein known to regulate synaptic protein translation, and its expression is reduced in the FUS-ALS lines. Collectively, our data suggest that a reduction of FMRP levels alters the synaptic protein dynamics, leading to synaptic dysfunction and glutamate excitotoxicity. Here, we present a mechanistic hypothesis linking dysregulation of peripheral translation with synaptic vulnerability in the pathogenesis of FUS-ALS.

Keywords: ALS; FMRP; FUS; amyotrophic lateral sclerosis; disease modelling; fragile X mental retardation protein; fused in sarcoma; iPSCs; induced pluripotent stem cells; neuronal degeneration; synaptic dysfunction.

MeSH terms

  • Adult
  • Amyotrophic Lateral Sclerosis* / pathology
  • Glutamates / metabolism
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Motor Neurons / metabolism
  • Mutation
  • RNA-Binding Protein FUS / genetics

Substances

  • Glutamates
  • RNA-Binding Protein FUS
  • FUS protein, human